Ignite Creation Date:
2024-05-06 @ 4:01 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04844827
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2021-04-12
Brief Title:
Pleural Carcinomatosis Tissue Banking
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Creation of a Pleural Carcinomatosis Tissue Bank
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TICP
Brief Summary:
Malignant pleural effusion is a common evolution of various cancers and is associated with poor prognosis and quality of life About 28 of patients with primary malignancy will develop pleural metastasis Malignant pleural effusion mostly occurs in lung breast ovarian and gastric cancers Median survival ranges from 3 to 13 months according to primary malignancy Currently the therapeutic approach is mainly palliative with videothoracoscopic talc pleurodesis or indwelling pleural catheters insertion eventually associated with systemic chemotherapy if patients general condition allows
In a early-disseminated tumor cells profile metastatic cells can accumulate alterations at a distant site and have a different profil from the original tumor cells Metastatic cells can also accumulate alterations in the course if systemic treatments Consequently they may respond differently to drugs
Recently EGFR mutations and ALK status discordance between primary tumors and pleural metastases have been demonstrated in a significant portion of lung adenocarcinomas These studies realized on malignant pleural effusion isolated cells enabled us to hypothesize a possible intratumoral heterogeneity within pleural metastases but no study has been carried out on pleural tissue
Our aim is to create a biocollection with tissues from pleural carcinomatosis in order to subsequently allow multiomics and bioinformatics analyzes and to characterize a possible intratumoral heterogeneity in pleural metastasis
In a early-disseminated tumor cells profile metastatic cells can accumulate alterations at a distant site and have a different profil from the original tumor cells Metastatic cells can also accumulate alterations in the course if systemic treatments Consequently they may respond differently to drugs
Recently EGFR mutations and ALK status discordance between primary tumors and pleural metastases have been demonstrated in a significant portion of lung adenocarcinomas These studies realized on malignant pleural effusion isolated cells enabled us to hypothesize a possible intratumoral heterogeneity within pleural metastases but no study has been carried out on pleural tissue
Our aim is to create a biocollection with tissues from pleural carcinomatosis in order to subsequently allow multiomics and bioinformatics analyzes and to characterize a possible intratumoral heterogeneity in pleural metastasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-A00761-40 | OTHER | ID-RCB | None |